This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
-
Mirador Therapeutics Selected Site, Little Rock, Arkansas, United States, 72205
Mirador Therapeutics Selected Site, Miami, Florida, United States, 33176
Mirador Therapeutics Selected Site, Orlando, Florida, United States, 32825
Mirador Therapeutics Selected Site, Snellville, Georgia, United States, 30078
Mirador Therapeutics Selected Site, Glenview, Illinois, United States, 60026
Mirador Therapeutics Selected Site, Shreveport, Louisiana, United States, 71105
Mirador Therapeutics Selected Site, Liberty, Missouri, United States, 64068
Mirador Therapeutics Selected Site, Rochester, New York, United States, 14618
Mirador Therapeutics Selected Site, Greenville, South Carolina, United States, 29607
Mirador Therapeutics Selected Site, Cordova, Tennessee, United States, 38018
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 80 Years
ALL
No
Mirador Therapeutics, Inc.,
2027-05-07